Discover a study showing barzolvolimab rapidly improves chronic spontaneous urticaria symptoms, offering hope for patients ...

According to the CDC, an estimated 1 in 13 children have food allergies. And at least 2 in 5 children, or 40 percent, have ...

First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic ...

Chronic urticaria affects 17% of patients, with higher age, elevated BMI, and early prednisolone use as key determinants of prolonged disease duration. The study utilized data from the Julius General ...

A total of 1 in 6 new urticaria cases become chronic, with older age, higher BMI, and early prednisolone use identified as key predictors, researchers find.

Barzolvolimab treatment demonstrated rapid and profound improvement in urticaria control with sustained efficacy, including after the completion of active therapy, in patients with CSU refractory to ...

How one woman went from a severe alopecia areata diagnosis to finding the right prescription treatment for her—and getting ...

1. Willi R, Bril V, Howard J, et al. RELIEVE: a phase 3 study evaluating the efficacy and safety of remibrutinb in generalized myasthenia gravis. Presented at: American Association of Neuromuscular & ...

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...

Two toddlers who had peanut allergy during infancy are now able to safely consume peanuts following a new protocol, according ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Many pregnant women experience allergies, asthma, or reactions to medications—conditions that can affect both mother and baby if not carefully managed. Yet new research presented at the 2025 American ...